COVID-19 (Coronavirus)

ASPIRE, Stroke Net

Condition: Stroke

Eligibility

Key Inclusion Criteria

  • At least 18 years old
  • Intracerebral hemorrhage (ICH) confirmed by brain computed tomography or magnetic resonance imaging
  • Can be assigned to a treatment group within 14-120 days after ICH onset

Key Exclusion Criteria

  • History of intracerebral hemorrhage before index event
  • Active infective endocarditis
  • Lobar ICH with high-risk cerebral amyloid angiopathy

Full Study Name

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE) (IRB no. 00000354)  

Phase
Phase III

Summary
This study focuses on adults who have had a recent brain hemorrhage and have also been diagnosed with an irregular heart rate (a condition known as atrial fibrillation). The purpose of the study is to compare the effects of a drug called apixaban with aspirin to determine which is more effective for the prevention of strokes and death. Survivors of intracerebral hemorrhage who have atrial fibrillation are at high risk for subsequent ischemic stroke (injury to the brain caused by a blocked blood vessel). Apixaban is approved by the U.S. Food and Drug Administration (FDA) for stroke prevention in patients with atrial fibrillation, but its use is investigational in this study.

Principal Investigator
Contact